Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus TROPICAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus TROPICAMIDE.
ANISOTROPINE METHYLBROMIDE vs TROPICAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Antimuscarinic agent that blocks acetylcholine at muscarinic receptors in the ciliary muscle and sphincter muscle of the iris, resulting in mydriasis and cycloplegia.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated in 5 minutes if needed for maximal effect; for cycloplegic refraction, 1-2 drops of 1% solution repeated in 5 minutes.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateTropicamide + Fesoterodine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life is approximately 2 hours; clinically, mydriasis and cycloplegia persist for 4-8 hours despite rapid plasma clearance.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Primarily renal excretion of unchanged drug and metabolites; approximately 30% unchanged in urine within 6 hours; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Anticholinergic
Anticholinergic
Tropicamide + Quinidine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine."